Study shows how HIV is shielded from immune attack

July 10, 2018, University of New South Wales
Inositol hexakisphosphate fits into the pore structures (pink) of the HIV capsid (teal), and makes the makes the capsid stronger, protecting the genetic material inside. Credit: UNSW

Scientists from UNSW Sydney and the UK have discovered that the human immunodeficiency virus (HIV) hijacks a small molecule from the host cell to protect itself from being destroyed by the host's immune system.

The finding, as well as details of the new strategy that enabled it, are published as back-to-back papers in eLife. They identify a new target for antiviral therapy against HIV and provide a method for testing and measuring new drugs designed to target the capsid.

UNSW Ph.D. student Chantal Márquez is involved in both studies and is the first author of the paper describing the new method.

HIV forms a protein shell—called a capsid—that shields its genetic material from host defence mechanisms as it enters the cell and makes its way to the nucleus to establish infection.

Using a new single-molecule microscopy technique—developed at UNSW's Single Molecule Science in the Faculty of Medicine—the research teams found that HIV specifically incorporates a small molecule from the host cell—inositol hexakisphosphate—to strengthen its capsid. The host inadvertently provides the key for the virus infecting it to lock down the protective shell, keeping the genetic cargo safe until it is released into the nucleus.

"The HIV capsid falls apart within minutes once it's isolated from the virus," said Associate Professor Till Böcking, who led the UNSW team involved in both studies.

"Our strategy lets us study exactly how a native capsid breaks apart in real-time without taking it out of the viral membrane."

With the help of Associate Professor Stuart Turville of the Kirby Institute, the team engineered viruses with fluorescent tags to monitor the viral capsid using fluorescence microscopy.

"We can now see the effect of different on the capsid, and pinpoint precisely when it cracks open and begins to collapse," says Associate Professor Böcking.

"Capsids need to be much more stable inside a cell because the infection process takes hours, not minutes—so we wanted to find out what keeps it stable inside a cell," says Dr. David Jacques of Single Molecule Science, who is an author of both studies.

The researchers found that inositol hexakisphosphate, which is abundantly present inside mammalian , makes the capsid much stronger, stabilizing it for 10-20 hours.

"It's like a switch. When you bind this molecule, you stabilize the capsid, and release the molecule to open it up," explains Associate Professor Böcking.

"The HIV capsid has been intensively studied, but the question of how it can simultaneously be both stable and poised to 'uncoat' has been one of the great unanswered questions in HIV biology," says Dr. Leo James, leader of the research team at the Medical Research Council Laboratory of Molecular Biology in Cambridge, UK.

Most of the currently approved HIV therapies target enzymes needed at different stages of the virus' life cycle, but none of them are directed at the HIV capsid. New drug alternatives could improve the treatment of HIV with reduced toxic effects.

Explore further: Research reveals new insights into hepatitis B

More information: Donna L Mallery et al, IP6 is an HIV pocket factor that prevents capsid collapse and promotes DNA synthesis, eLife (2018). DOI: 10.7554/eLife.35335

Related Stories

Research reveals new insights into hepatitis B

June 1, 2018
Researchers at the University of Delaware, working with colleagues at Indiana University, have gained new insights into the virus that causes hepatitis B—a life-threatening and incurable infection that afflicts more than ...

Cryo-electron microscopy reveals common herpes virus structure

July 5, 2018
For the first time, researchers have been able to use cryo-electron microscopy, to reveal the detailed structure of the common herpes virus.

Scientists reveal cryo-electron microscopy structure of a herpesvirus capsid at 3.1 Angstrom

April 5, 2018
The herpesvirus is genetically and structurally one of the most complex viruses. It spreads within the host population efficiently, causing a range of diseases in humans, including congenital disorders and cancers.

Massive simulation shows HIV capsid interacting with its environment

July 19, 2017
It took two years on a supercomputer to simulate 1.2 microseconds in the life of the HIV capsid, a protein cage that shuttles the HIV virus to the nucleus of a human cell. The 64-million-atom simulation offers new insights ...

Molecules seen binding to HIV-1's protective capsule, blocking infection

December 30, 2014
Imagine a suitcase on a bumpy ride. With enough jostling it opens, spilling clothes everywhere. Similarly awkward, the suitcase locks may jam and not open at the destination.

Discovery of key component of HIV virus yields new drug target

August 10, 2016
Scientists from the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge and University College London have discovered an essential feature of the HIV virus that it uses to infect cells whilst avoiding ...

Recommended for you

Proof-of-concept HIV immunotherapy study passes Phase 1 safety trial

September 21, 2018
Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals previously ...

FRESH program combines basic science with social benefits for women at risk of HIV

September 14, 2018
A program established by investigators from the Ragon Institute of Massachusetts General Hospital (MGH), MIT and Harvard is addressing the persistently elevated risk of HIV infection among young women in South Africa from ...

New study finds HIV outbreak in Indiana could have been prevented

September 13, 2018
An HIV outbreak among people who inject drugs in Indiana from 2011 to 2015 could have been avoided if the state's top health and elected officials had acted sooner on warnings, a new study by the Yale School of Public Health ...

Largest study of 'post-treatment controllers' reveals clues about HIV remission

September 13, 2018
Most HIV patients need to take daily anti-retroviral therapy—if they suspend treatment, HIV will rebound within 3-4 weeks. But clinical trials have revealed that a small fraction of patients can stop taking medications ...

Very few sexually active gay and bisexual men use prophylactic drug to prevent HIV transmission, study finds

September 12, 2018
Only 4 percent of sexually active gay and bisexual men in the United States use Truvada, a highly effective medication used to prevent the transmission of HIV, according to the results of a first-of-its-kind study.

Special antibodies could lead to HIV vaccine

September 10, 2018
Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers from the ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym222368
not rated yet Aug 10, 2018
THANKS for sharing this
Generic Atripla
Viraday
Trustiva
Atripla Generic 2018
efavirenz +TDF+FTC
Efavirenz 600mg + Emtricitabine 200mg +Tenofovir disoproxil fumarate 300mg,
atripla generic
generic Atripla India
Trustiva

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.